POMT2 sirna

POMT2 siRNA (Human)

Cat. Num. AAA8230502

• Gene Names: POMT2; LGMD2N; MDDGA2; MDDGB2; MDDGC2
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: POMT2; POMT2 siRNA (Human); Protein O-mannosyl-transferase 2; Dolichyl-phosphate-mannose--protein mannosyltransferase 2; POMT2 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: POMT2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 750

• Applicable Applications for POMT2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human POMT2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for POMT2 sirna

siRNA to inhibit POMT2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 32455271
• NCBI GeneID: 29954
• NCBI Accession #: NP_037514.2
• NCBI GenBank Nucleotide #: NM_013382.5
• UniProt Accession #: Q9UKY4; Q9NSG6; Q9P1W0; Q9P1W2
• Molecular Weight: 8,899 Da
• NCBI Official Full Name: protein O-mannosyl-transferase 2
• NCBI Official Synonym Full Names: protein-O-mannosyltransferase 2
• NCBI Official Symbol: POMT2
• NCBI Official Synonym Symbols: LGMD2N; MDDGA2; MDDGB2; MDDGC2
• NCBI Protein Information: protein O-mannosyl-transferase 2
• UniProt Protein Name: Protein O-mannosyl-transferase 2
• Protein Family: Protein O-mannosyl-transferase
• UniProt Gene Name: POMT2
• UniProt Entry Name: POMT2_HUMAN

NCBI Description

The protein encoded by this gene is an O-mannosyltransferase that requires interaction with the product of the POMT1 gene for enzymatic function. The encoded protein is found in the membrane of the endoplasmic reticulum. Defects in this gene are a cause of Walker-Warburg syndrome (WWS).[provided by RefSeq, Oct 2008]

Uniprot Description

POMT2: Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient. Defects in POMT2 are the cause of muscular dystrophy- dystroglycanopathy congenital with brain and eye anomalies type A2 (MDDGA2); also called Walker-Warburg syndrome or muscle-eye-brain disease POMT2-related. MDDGA2 is a autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound mental retardation, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease. Defects in POMT2 are the cause of muscular dystrophy- dystroglycanopathy congenital with mental retardation type B2 (MDDGB2); also called muscular dystrophy congenital POMT2-related. MDDGB2 is an autosomal recessive disorder characterized by congenital muscular dystrophy associated with mental retardation and mild structural brain abnormalities. Defects in POMT2 are the cause of muscular dystrophy- dystroglycanopathy limb-girdle type C2 (MDDGC2); also called limb-girdle muscular dystrophy type 2N (LGMD2N) or muscular dystrophy-dystroglycanopathy limb-girdle POMT2-related (MDGD2C). MDDGC2 is an autosomal recessive muscular dystrophy with onset after ambulation is achieved. MDDGC2 is characterized by increased serum creatine kinase and mild muscle weakness. Muscle biopsy shows dystrophic changes, inflammatory changes, and severely decreased alpha-dystroglycan. Cognition is normal. Belongs to the glycosyltransferase 39 family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, integral; Glycan Metabolism - O-mannosyl glycan biosynthesis; Membrane protein, multi-pass; Transferase; Endoplasmic reticulum; EC 2.4.1.109

Chromosomal Location of Human Ortholog: 14q24

Cellular Component: endoplasmic reticulum membrane; integral to membrane

Molecular Function: metal ion binding; dolichyl-phosphate-mannose-protein mannosyltransferase activity

Biological Process: protein amino acid O-linked mannosylation

Disease: Muscular Dystrophy-dystroglycanopathy (congenital With Mental Retardation), Type B, 2; Muscular Dystrophy-dystroglycanopathy (limb-girdle), Type C, 2; Muscular Dystrophy-dystroglycanopathy (congenital With Brain And Eye Anomalies), Type A, 2; Muscular Dystrophy-dystroglycanopathy (congenital With Brain And Eye Anomalies), Type A, 1